



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶:

A61K 35/413

A1

(11) International Publication Number:

WO 96/28175

(43) International Publication Date: 19 September 1996 (19.09.96)

(21) International Application Number: PCT/CA96/00152

(22) International Filing Date: 13 March 1996 (13.03.96)

(30) Priority Data:

08/404,932

16 March 1995 (16.03.95)

US

(71) Applicant: IMUTEC CORPORATION [CA/CA]; 1285 Morningside Avenue, Scarborough, Ontario M1B 3W2 (CA).

(72) Inventors: RANG, Romeo; SOS, Oltenitei 248-123, ap. 15, SC. 1, ET11, R-Bucharest 4 (RO). PERCHESON, Paul, B.; 4300 Concession 7, RR #4, Uxbridge, Ontario L9P 1R4 (CA).

(74) Agent: CÔTÉ, France; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montreal, Quebec H3A 2Y3 (CA).


(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: IMMUNOMODULATING COMPOSITIONS FROM BILE FOR THE TREATMENT OF IMMUNE SYSTEM DISORDERS



(57) Abstract

The present invention relates to a composition for use as an immunomodulator comprising small molecular weight components of less than 3000 daltons, and having the following properties: (a) is extractable from bile of animals; (b) is capable of stimulating monocytes and macrophages *in vitro* and *in vivo*; (c) is capable of modulating tumor necrosis factor production; (d) contains no measurable IL-1 α , IL-1 β , TNF, IL-6, IL-8, IL-4, GM-CSF or IFN- γ ; (e) has an anti-proliferative effect in a malignant mouse hybridoma cell line; (f) shows no cytotoxicity to human peripheral blood mononuclear cells or lymphocytes; and (g) is not an endotoxin. The invention also relates to a method of preparing the composition, its use as an immunomodulator, and its use in the treatment of diseases and conditions having an immunological component, such as cancer or endometriosis.